Medigene Balance Sheet Health
Financial Health criteria checks 4/6
Medigene has a total shareholder equity of €19.7M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €28.8M and €9.2M respectively.
Key information
0%
Debt to equity ratio
€0
Debt
Interest coverage ratio | n/a |
Cash | €14.02m |
Equity | €19.66m |
Total liabilities | €9.15m |
Total assets | €28.81m |
Recent financial health updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29Recent updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
Aug 12Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
Aug 10We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 16How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23Financial Position Analysis
Short Term Liabilities: MDG1's short term assets (€15.6M) exceed its short term liabilities (€6.5M).
Long Term Liabilities: MDG1's short term assets (€15.6M) exceed its long term liabilities (€2.6M).
Debt to Equity History and Analysis
Debt Level: MDG1 is debt free.
Reducing Debt: MDG1 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDG1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MDG1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/25 06:20 |
End of Day Share Price | 2025/01/24 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigene AG is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Xian Deng | Berenberg |
Gary Waanders | Bryan Garnier & Co |
Christian Orquera | First Berlin Equity Research GmbH |